FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis - Pharmaceutical Executive
FDA approves Eli Lilly’s Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children aged 12+ weighing at least 88 lbs. Ebglyss targets the IL-13 pathway, with 38% achieving clear or almost-clear skin at 16 weeks vs. 12% on placebo. Common AEs include eye and eyelid inflammation, injection site reactions, and shingles.
Reference News
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis - Pharmaceutical Executive
FDA approves Eli Lilly’s Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children aged 12+ weighing at least 88 lbs. Ebglyss targets the IL-13 pathway, with 38% achieving clear or almost-clear skin at 16 weeks vs. 12% on placebo. Common AEs include eye and eyelid inflammation, injection site reactions, and shingles.